4 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
Follow Anal Squamous Cell Carcinoma: new trials by email Literature Review of Anal Squamous Cell Carcinoma trials Research Report on Anal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Retifanlimab After Chemoradiation in People With Anal Cancer Retifanlimab - Anal Squamous Cell Carcinoma, Anal Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 25 | 2026-11-04 | 2026-11-10 |
| Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer Lenvatinib, Pembrolizumab - Anal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 17 | 2026-09-30 | 2026-07-02 |
| MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach Radiotherapy - Low risk group, Radiotherapy - Standard risk group, Radiotherapy - Intermediate risk group - Anal Squamous Cell Carcinoma | Phase 2 | Recruiting | University Health Network, Toronto | 80 | 2023-09-29 | 2026-06-10 |
| Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers Regorafenib in combination with Tislelizumab - Anal Squamous Cell Carcinoma, Colorectal Neoplasms | Phase 2 | Withdrawn | Translational Research in Oncology | 2023-04-30 | 2023-06-07 | |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Anoscopy, Biospecimen Collection, Capecitabine - AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2022-08-09 | 2026-11-18 |
| PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients Toripalimab - Anal Canal Cancer, Anal Squamous Cell Carcinoma | Phase 2 | Completed | Sun Yat-sen University | 25 | 2021-10-27 | 2024-12-03 |
| Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Capecitabine, Carboplatin, Cisplatin - Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma | Phase 2 | Unknown | ECOG-ACRIN Cancer Research Group | 91 | 2016-08-23 | 2023-06-22 |
| Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Therapeutic Conventional Surgery - Anal Squamous Cell Carcinoma, HIV Infection | Phase 2 | Completed | AIDS Malignancy Consortium | 16 | 2015-04-01 | 2026-04-20 |
| Oral Rigosertib for Squamous Cell Carcinoma rigosertib - Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma | Phase 2 | Completed | Traws Pharma, Inc. | 64 | 2013-03-01 | 2017-06-26 |
| Vectibix for the Treatment of Anal Cancer panitumumab, mytomicin C, 5-FU, radiation - Anal Squamous Cell Carcinoma | Phase 2 | Completed | Grupo Espanol Multidisciplinario del Cancer Digestivo | 58 | 2010-10-01 | 2018-05-16 |
Anus Neoplasms (10) · Anal Canal Carcinoma (3) · HIV Infections (2) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Mesothelioma, Malignant (1) · Rectal Neoplasms (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Anus Diseases (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Gastrointestinal Diseases (10) · Gastrointestinal Neoplasms (10) · Intestinal Diseases (10) · Intestinal Neoplasms (10) · Neoplasms (10) · Neoplasms by Site (10) · Rectal Diseases (10) · Colorectal Neoplasms (9) · Rectal Neoplasms (9) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2)
Fluorouracil (3) · Capecitabine (2) · Radiation (2) · dehydroftorafur (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Carboplatin (1) · Cisplatin (1) · Colonoscopy (1) · Fluorodeoxyglucose F18 (1) · Magnetic Resonance Spectroscopy (1) · Mitomycin (1) · Mitozytrex (1) · Nivolumab (1) · ON 01910 (1) · Paclitaxel (1)
AIDS Malignancy Consortium (1) · ECOG-ACRIN Cancer Research Group (1) · Grupo Espanol Multidisciplinario del Cancer Digestivo (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Sun Yat-sen University (1) · Translational Research in Oncology (1) · Traws Pharma, Inc. (1) · University Health Network, Toronto (1) · University of Texas Southwestern Medical Center (1)
United States (6) · Australia (1) · Canada (1) · China (1) · Spain (1)
Aleydis Pisa, MD (1) · Antonio Arrivi, MD (1) · Cathy Eng (1) · Clara Montagut, MD (1) · Emilio Fonseca, MD (1) · Fernando Rivera, MD (1) · I Guasch, MD (1) · Isabel Sevilla, MD (1) · Jaime Feliu, MD (1) · Jaume Capdevila, MD (1) · Jesus Garcia-Foncillas, MD (1)
PMID 15629599, PMID 17103253, PMID 18430910, PMID 19801930, PMID 20354531, PMID 20436836, PMID 20956625, PMID 21240983, PMID 21514072, PMID 23484057, PMID 23578724, PMID 28055103, PMID 28223062, PMID 28453692, PMID 28463160, PMID 29755663, PMID 29878949, PMID 30264638, PMID 31288054, PMID 31534737, PMID 32530769, PMID 8348857, PMID 8874455, PMID 9164216
U01CA121947 (1), U10CA180820 (1), UM1CA121947 (1)